Antoni Ribas
Melanoma immunotherapy leader behind pembrolizumab's first trials and the science of why immunotherapy fails.
Medical oncologist who led the earliest pembrolizumab studies in melanoma (KEYNOTE-001) and defined resistance mechanisms such as JAK1/2 and B2M loss. Past president of AACR and a founder of cell-therapy and TCR companies.
| Title | Journal | Year |
|---|---|---|
| Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma | New England Journal of Medicine | 2016 |
| Cancer immunotherapy using checkpoint blockade | Science | 2018 |
Pages like this
not linked directly; found by shared links- TrialKEYNOTE-006
Shares PD-1, Pembrolizumab, Melanoma, Immune checkpoint inhibitors.
- CollectionMelanoma Research Alliance (MRA)
- PersonTasuku Honjo
Shares PD-1, Pembrolizumab, Melanoma, Immune checkpoint inhibitors.
- IdeaRandomised trials of stopping immunotherapy after one year versus continuing
Shares PD-1, Pembrolizumab, Melanoma, Immune checkpoint inhibitors.
- IdeaAn advance market commitment for PD-1 biosimilars for lower-income countries
Shares PD-1, Pembrolizumab, Immune checkpoint inhibitors.
- IdeaExtended-interval immunotherapy: give checkpoint inhibitors every 8-12 weeks once stable
Shares PD-1, Pembrolizumab, Melanoma, Immune checkpoint inhibitors.
- PairingPD-1 failure → TIL therapy
Shares Pembrolizumab, Melanoma, Immune checkpoint inhibitors.
- IdeaBRAF/MEK plus PD-1 blockade as standard for BRAF-mutant anaplastic thyroid cancer
Shares BRAF, PD-1, Pembrolizumab.